Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / ADS
-
Number of holders
-
54
-
Total 13F shares, excl. options
-
18.9M
-
Shares change
-
-3.03M
-
Total reported value, excl. options
-
$107M
-
Value change
-
-$14.7M
-
Put/Call ratio
-
0
-
Number of buys
-
20
-
Number of sells
-
-31
-
Price
-
$5.80
Significant Holders of Silence Therapeutics plc - ADS (SLN) as of Q2 2025
70 filings reported holding SLN - Silence Therapeutics plc - ADS as of Q2 2025.
Silence Therapeutics plc - ADS (SLN) has 54 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.9M shares
.
Largest 10 shareholders include TCG Crossover Management, LLC (3.03M shares), Siren, L.L.C. (2.91M shares), Redmile Group, LLC (2.16M shares), Lombard Odier Asset Management (USA) Corp (1.85M shares), MORGAN STANLEY (1.21M shares), Vivo Capital, LLC (1.11M shares), Nantahala Capital Management, LLC (1.04M shares), Frazier Life Sciences Management, L.P. (970K shares), Nextech Invest, Ltd. (952K shares), and CANTOR FITZGERALD, L. P. (789K shares).
This table shows the top 54 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.